Excitation of locus coeruleus noradrenergic neurons by thyrotropin-releasing hormone.
Locus coeruleus (LC) noradrenergic neurons are implicated in a variety of functions including the regulation of vigilance and the modulation of sensory processing. Thyrotropin-releasing hormone (TRH) is an endogenous neuropeptide that induces a variety of behavioural changes including arousal and antinociception. In the present study, we explored whether the activity of LC noradrenergic neurons is modulated by TRH. Using current-clamp recording from isolated rat LC neurons, we found that TRH increased the firing rate of spontaneous action potentials. The TRH action was mimicked by TRH analogues including taltirelin and TRH-gly. In voltage-clamp recording at a holding potential of 50 mV, TRH produced an inward current associated with a decrease in the membrane K+ conductance. This current was inhibited by the TRH receptor antagonist chlordiazepoxide. Following inhibition of the pH-sensitive K+ conductance by extracellular acidification, the TRH response was fully inhibited. The TRH-induced current was also inhibited by the phospholipase C (PLC) inhibitor U-73122, but not by the protein kinase C inhibitor chelerythrine nor by chelation of intracellular Ca2+ by BAPTA. The recovery from the facilitatory action of TRH on the spike frequency was markedly inhibited by a high concentration of wortmannin. These results suggest that TRH activates LC noradrenergic neurons by decreasing an acid-sensitive K+ conductance via PLC-mediated hydrolysis of phosphatidylinositol 4,5-bisphosphate. The present findings demonstrate that TRH activates LC neurons and characterize the underlying signalling mechanisms. The action of TRH on LC neurons may influence a variety of CNS functions related to the noradrenergic system which include arousal and analgesia.
Ishibashi
Hitoshi
H
Division of Homeostatic Development, Department of Developmental Physiology, National Institute for Physiological Sciences, Okazaki, 444-8585, Japan. isibasi@nips.ac.jp
Nakahata
Yoshihisa
Y
Eto
Kei
K
Nabekura
Junichi
J
D000200:Action Potentials; D000779:Anesthetics, Local / Q000494:pharmacology; D000818:Animals; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology; D002707:Chlordiazepoxide / Q000494:pharmacology; D004594:Electrophysiology; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D008125:Locus Coeruleus / Q000166:cytology / Q000187:drug effects* / Q000502:physiology*; D009474:Neurons / Q000187:drug effects* / Q000502:physiology*; D009638:Norepinephrine / Q000502:physiology*; D018408:Patch-Clamp Techniques; D026902:Potassium Channel Blockers / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D018025:Receptors, Thyrotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D012996:Solutions; D013779:Tetrodotoxin / Q000494:pharmacology; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors
D000779:Anesthetics, Local; D006993:Hypnotics and Sedatives; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D018025:Receptors, Thyrotropin-Releasing Hormone; D012996:Solutions; D013779:Tetrodotoxin; D013973:Thyrotropin-Releasing Hormone; D002707:Chlordiazepoxide; D011493:Protein Kinase C; D010738:Type C Phospholipases; D009638:Norepinephrine